|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Electro-dewatering of wastewater sludge: Influence of the operating conditions and their interactions effects显示文摘 | Akrama Mahmoud Jérémy Olivier Jean Vaxelaire Andrew F.A. Hoadley | 2011 | Water Research2011，，9： | 1 |
| 2 | Tranexamic acid for intracerebral haemorrhage within 2 hours of onset: protocol of a phase Ⅱ randomised placebo-controlled double-blind multicentre trial显示文摘Rationale Haematoma growth is common early after intracerebral haemorrhage(ICH),and is a key determinant of outcome.Tranexamic acid,a widely available antifibrinolytic agent with an excellent safety profile,may reduce haematoma growth.Methods and design Stopping intracerebral haemorrhage with tranexamic acid for hyperacute onset presentation including mobile stroke units(STOP-MSU)is a phase Ⅱ double-blind,randomised,placebo-controlled,multicentre,international investigator-led clinical trial,conducted within the estimand statistical framework.Hypothesis In patients with spontaneous ICH,treatment with tranexamic acid within 2 hours of onset will reduce haematoma expansion compared with placebo.Sample size estimates A sample size of 180 patients(90 in each arm)would be required to detect an absolute difference in the primary outcome of 20%(placebo 39%vs treatment 19%)under a two-tailed significance level of 0.05.An adaptive sample size re-estimation based on the outcomes of 144 patients will allow a possible increase to a prespecified maximum of 326 patients.Intervention Participants will receive 1 g intravenous tranexamic acid over 10 min,followed by 1 g intravenous tranexamic acid over 8 hours;or matching placebo.Primary efficacy measure The primary efficacy measure is the proportion of patients with haematoma growth by 24±6 hours,defined as either≥33%relative increase or≥6 mL absolute increase in haematoma volume between baseline and follow-up CT scan.Discussion We describe the rationale and protocol of STOP-MSU,a phase Ⅱ trial of tranexamic acid in patients with ICH within 2 hours from onset,based in participating mobile stroke units and emergency departments. | Nawaf Yassi Henry Zhao Leonid Churilov Bruce C V Campbell Teddy Wu Henry Ma Andrew Cheung Timothy Kleinig Helen Brown Philip Choi Jiann-Shing Jeng Annemarei Ranta Hao-Kuang Wang Geoffrey C Cloud Rohan Grimley Darshan Shah Neil Spratt Der-Yang Cho Karim Mahawish Lauren Sanders John Worthington Ben Clissold Atte Meretoja Vignan Yogendrakumar Mai Duy Ton Duc Phuc Dang Nguyen Thai My Phuong Huy-Thang Nguyen Chung Y Hsu Gagan Sharma Peter J Mitchell Bernard Yan Mark W Parsons Christopher Levi Geoffrey A Donnan Stephen M Davis | 2022 | Stroke & Vascular Neurology2022，7，2： | 1 |
| 3 | Expression and regulation of Bcl- 2 Bcl - xL and Bax correlate with P53 status and sensitivity to apopto- sis in ALL显示文摘 | Harry WF Andrew MY | 1997 | Blood1997，89，8： | 1 |
| 4 | Noninvasive arterial studies including transcutaneous oxygen pressure measurements with the limbs elevated or dependent to predict healing after par- tial foot amputation 显示文摘 | Andrews KL Dib MY Shires TC | 2013 | Am J Phys Med Rehabil2013，92，5： | 1 |
| 5 | Successful management of spind dural arteriovenous fistulas undetected by ar- teriography显示文摘 | Oldfield EH Andrew BZ Chen MY | 2002 | J Neurosurg2002，96，2： | 1 |
| 6 | Noninvasive arterial stud- ies including transcutaneous oxygen pressure measurements with the limbs elevated or dependent to predict healing after partial foot amputation显示文摘 | Andrews KL Dib MY Shives TC | 2013 | Am J Phys Med Rehabil2013，92，5： | 1 |
| 7 | Successful management of spinal dural arteriovenous fistulas undetected by arteriography显示文摘 | Oldfield EH Andrew BE Chen MY | 2002 | J Neurosurg2002，96，2： | 1 |
| 8 | The global COVID-19 vaccine surplus:tackling expiring stockpiles显示文摘Background A global surplus of coronavirus disease 2019(COVID-19)vaccines exists as a result of difficulties in aligning the demand and supply for vaccine manufacturing and delivery.World leaders have accelerated vaccine development,approval,production and distribution as a pragmatic approach to addressing the immediate public health challenges of the first two and a half years of the pandemic.Main body The currently predominant,highly transmissible Omicron variant of severe acute respiratory syndrome coronavirus 2 has brought us closer to the threshold required to achieve herd immunity by greatly increasing rates of natural infection.Paradoxically,in parallel with rising vaccination levels in industrialized nations,this indirectly reduces the need for mass vaccine campaigns.Principal concerns that contribute to low vaccination rates which persist in several other countries,particularly of the Global South,are vaccine hesitancy and unequal access to vaccination.Social uncertainty fueled by fake news,misinformation,unfounded lay opinions and conspiracy theories has inevitably led to an erosion of public trust in vaccination.Conclusion To address the current mismatch between supply and demand of COVID-19 vaccines,there should be a focus on three principles:decelerating vaccine production,increasing distribution across communities,and optimizing cost-effectiveness of distribution logistics.Slowing down and switching from large-scale production to effectively‘made to order’is a feasible option,which should be commensurate with management capacity.Transparent and evidence-based data should be widely and freely disseminated to the public through multimedia channels to mitigate miscommunication and conspiracy theories.Use of soon-to-expire stockpiles should be prioritized not only to enhance booster dose rollouts in adults but to expand immunization campaigns to children(especially those aged 5–11 years),subject to national approval.Future research should ideally aim to develop vaccines that only require basic,affordable storage and maintenance procedures as opposed to sophisticated and expensive protocols. | Nguyen Khoi Quan Nguyen Le My Anh Andrew W.Taylor-Robinson | 2023 | Infectious Diseases of Poverty2023，12，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员